Advice
following an abbreviated submission
efavirenz (Sustiva®) is accepted for use within NHS Scotland.
Indication under review: antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.
For patients at least 3 months old and weighing at least 3.5kg who cannot swallow capsules, the capsule contents can be administered with a small amount of food using the capsule sprinkle method of administration.
Efavirenz is listed in the British National Formulary for Children for the treatment of HIV infection.
Download detailed advice51KB (PDF)
Medicine details
- Medicine name:
- efavirenz (Sustiva)
- SMC ID:
- 1125/15
- Indication:
- antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd / AstraZeneca
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 07 December 2015